Structural and mechanistic bases for a potent HIV-1 capsid inhibitor.
Stephanie M BesterGuochao WeiHaiyan ZhaoDaniel Adu-AmpratwumNaseer IqbalValentine V CouroubleAshwanth C FrancisArun S AnnamalaiParmit Kumar SinghNikoloz ShkriabaiPeter van BlerkomJames H MorrisonEric M PoeschlaAlan N EngelmanGregory B MelikyanPatrick R GriffinJoanna E BurdetteFrancisco J AsturiasMamuka KvaratskheliaPublished in: Science (New York, N.Y.) (2020)
The potent HIV-1 capsid inhibitor GS-6207 is an investigational principal component of long-acting antiretroviral therapy. We found that GS-6207 inhibits HIV-1 by stabilizing and thereby preventing functional disassembly of the capsid shell in infected cells. X-ray crystallography, cryo-electron microscopy, and hydrogen-deuterium exchange experiments revealed that GS-6207 tightly binds two adjoining capsid subunits and promotes distal intra- and inter-hexamer interactions that stabilize the curved capsid lattice. In addition, GS-6207 interferes with capsid binding to the cellular HIV-1 cofactors Nup153 and CPSF6 that mediate viral nuclear import and direct integration into gene-rich regions of chromatin. These findings elucidate structural insights into the multimodal, potent antiviral activity of GS-6207 and provide a means for rationally developing second-generation therapies.
Keyphrases
- antiretroviral therapy
- hiv positive
- hiv infected
- human immunodeficiency virus
- hiv aids
- hiv infected patients
- electron microscopy
- hiv testing
- hepatitis c virus
- men who have sex with men
- south africa
- genome wide
- high resolution
- gene expression
- sars cov
- magnetic resonance
- anti inflammatory
- minimally invasive
- transcription factor
- induced apoptosis
- cell proliferation
- dna methylation
- endoplasmic reticulum stress
- oxidative stress
- clinical trial